Effect of Aspirin Versus Low-Molecular-Weight Heparin Thromboprophylaxis on Medication Satisfaction and Out-of-Pocket Costs
Journal of Bone and Joint Surgery · 2024
DOI: 10.2106/jbjs.23.00824 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Joint Surgery, 2024. Verfasst von Nathan N O'Hara und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Venous Thromboembolism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Current guidelines recommend low-molecular-weight heparin for thromboprophylaxis after orthopaedic trauma. However, recent evidence suggests that aspirin is similar in efficacy and safety. To understand patients’ experiences with these medications, we compared patients’ satisfaction and out-of-pocket costs after thromboprophylaxis with aspirin versus low-molecular-weight heparin.
Methods
This study was a secondary analysis of the PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT) trial, conducted at 21 trauma centers in the U.S. and Canada. We included adult patients with an operatively treated extremity fracture or a pelvic or acetabular fracture. Patients were randomly assigned to receive 30 mg of low-molecular-weight heparin (enoxaparin) twice daily or 81 mg of aspirin twice daily for thromboprophylaxis. The duration of the thromboprophylaxis, including post-discharge prescription, was based on hospital protocols. The study outcomes included patient satisfaction with and out-of-pocket costs for their thromboprophylactic medication measured on ordinal scales.
Results
The trial enrolled 12,211 patients (mean age and standard deviation [SD], 45 ± 18 years; 62% male), 9725 of whom completed the question regarding their satisfaction with the medication and 6723 of whom reported their out-of-pocket costs. The odds of greater satisfaction were 2.6 times higher for patients assigned to aspirin than those assigned to low-molecular-weight heparin (odds ratio [OR]: 2.59; 95% confidence interval [CI]: 2.39 to 2.80; p < 0.001). Overall, the odds of incurring any out-of-pocket costs for thromboprophylaxis medication were 51% higher for patients assigned to aspirin compared with low-molecular-weight heparin (OR: 1.51; 95% CI: 1.37 to 1.66; p < 0.001). However, patients assigned to aspirin had substantially lower odds of out-of-pocket costs of at least $25 (OR: 0.15; 95% CI: 0.12 to 0.18; p < 0.001).
Conclusions
Use of aspirin substantially improved patients’ satisfaction with their medication after orthopaedic trauma. While aspirin use increased the odds of incurring any out-of-pocket costs, it protected against costs of ≥$25, potentially improving health equity for thromboprophylaxis. Level of Evidence: Therapeutic Level II . See Instructions for Authors for a complete description of levels of evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland.
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
- Department of Surgery, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland.
- Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington.
- Department of Orthopaedic Surgery, Atrium Health Carolinas Medical Center, Charlotte, North Carolina.
- Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California.
ORCID-Profile: Katherine P Frey, Deborah M Stein, Joseph F Levy, Gerard P Slobogean, Renan Castillo, Reza Firoozabadi, Madhav A Karunakar, Joshua L Gary, William T Obremskey, Rachel B Seymour, Joseph Cuschieri, C Daniel Mullins, Robert V O'Toole
Zitieren
APA
O'Hara, N. N., Frey, K. P., Stein, D. M., Levy, J. F., Slobogean, G. P., Castillo, R., Firoozabadi, R., Karunakar, M. A., Gary, J. L., Obremskey, W. T., Seymour, R. B., Cuschieri, J., Mullins, C. D., O'Toole, R. V., & METRC (2024). Effect of Aspirin Versus Low-Molecular-Weight Heparin Thromboprophylaxis on Medication Satisfaction and Out-of-Pocket Costs. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.23.00824
Vancouver
O'Hara NN, Frey KP, Stein DM, Levy JF, Slobogean GP, Castillo R, et al. Effect of Aspirin Versus Low-Molecular-Weight Heparin Thromboprophylaxis on Medication Satisfaction and Out-of-Pocket Costs. Journal of Bone and Joint Surgery. 2024. doi:10.2106/jbjs.23.00824
BibTeX
@article{OHara2024,
author = {O'Hara, Nathan N and Frey, Katherine P and Stein, Deborah M and Levy, Joseph F and Slobogean, Gerard P and Castillo, Renan and Firoozabadi, Reza and Karunakar, Madhav A and Gary, Joshua L and Obremskey, William T and Seymour, Rachel B and Cuschieri, Joseph and Mullins, C Daniel and O'Toole, Robert V and METRC, METRC},
title = {Effect of Aspirin Versus Low-Molecular-Weight Heparin Thromboprophylaxis on Medication Satisfaction and Out-of-Pocket Costs},
journal = {Journal of Bone and Joint Surgery},
year = {2024},
doi = {10.2106/jbjs.23.00824}
}
EUVIMED